Bayer Schering Pharma Ag

Schering Aktiengesellschaft

Bayer Healthcare LLC

Bayer Intellectual Property Gmbh

Bayer Pharma Aktiengesellschaft

Richard N Harkins

Gordon Parry

Douglas W Schneider

Deborah Parkes

Renate Parry

Terry Hermiston

Maxine Bauzon

Bradley A Katz

Peter Kretschmer

Fang Jin

Renate Steinbrecher

Marian Seto

Peter Droescher

Paul Szymanski

Konstantin Levitsky

Douglas Schneider

The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consisting of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.

Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells

The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to antibodies directed against the polypeptides and to methods for using the polynucleotides, and polypeptides, and antibodies in research, diagnosis, and therapeutic applications.

Isolated human antibodies that bind epitopes on RG1

Methods for treating disease-states associated with RG1 using immunoconjugates

The present invention relates to antibodies, and antigen-binding antibody fragments, directed against an RG1 polypeptide. The invention further relates to methods for utilizing the antibodies, and antibody fragments, for diagnostic and therapeutic applications.

RG1 antibodies and uses thereof

The present invention relates to novel human extracellular matrix polypeptides, designated RG1, polynucleotides encoding the polypeptides, methods for producing the polypeptides, expression vectors and genetically engineered host cells for expression of the polypeptides. The invention further relates to methods for utilizing the polynucleotides and polypeptides in research, diagnosis, and therapeutic applications.

DNA encoding a novel RG1 polypeptide

The invention provides for synthetic ligands that bind to class I receptor tyrosine kinases. The ligands are analogous in structure to naturally occurring ligands. The modified ligands however, have eliminated the mid-sequence (B) domain present in the native ligands and replaced it with a peptide bridge which links the amino (A) and carboxy (C) domains.

Modified ligands for receptor tyrosine kinases

Growing community of inventors

Alameda, CA, United States of America

Richard N Harkins